EPS for Novartis AG (NVS) Expected At $1.16

January 18, 2018 - By Nellie Frank

 EPS for Novartis AG (NVS) Expected At $1.16

Analysts expect Novartis AG (NYSE:NVS) to report $1.16 EPS on January, 24.They anticipate $0.04 EPS change or 3.57 % from last quarter’s $1.12 EPS. NVS’s profit would be $2.73 billion giving it 18.67 P/E if the $1.16 EPS is correct. After having $1.29 EPS previously, Novartis AG’s analysts see -10.08 % EPS growth. The stock decreased 0.31% or $0.27 during the last trading session, reaching $86.61. About 547,260 shares traded. Novartis AG (NYSE:NVS) has risen 7.67% since January 18, 2017 and is uptrending. It has underperformed by 9.03% the S&P500.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 16 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 4 Sell and 7 Hold. Therefore 31% are positive. Novartis Ag has $110 highest and $7700 lowest target. $93.40’s average target is 7.84% above currents $86.61 stock price. Novartis Ag had 34 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Monday, October 23 by Leerink Swann. The rating was maintained by Cowen & Co on Wednesday, August 9 with “Hold”. The firm earned “Neutral” rating on Wednesday, April 19 by JP Morgan. The stock of Novartis AG (NYSE:NVS) has “Sell” rating given on Wednesday, December 6 by Bank of America. Leerink Swann downgraded it to “Market Perform” rating and $85 target in Wednesday, March 23 report. J P Morgan Chase Co maintained the shares of NVS in report on Friday, June 16 with “Neutral” rating. The rating was upgraded by Societe Generale to “Buy” on Wednesday, March 8. The stock of Novartis AG (NYSE:NVS) earned “Hold” rating by Cowen & Co on Friday, October 13. Argus Research upgraded Novartis AG (NYSE:NVS) on Thursday, November 10 to “Buy” rating. The stock of Novartis AG (NYSE:NVS) earned “Buy” rating by Chardan Capital Markets on Monday, October 10.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $203.98 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 30.86 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.